E

Endo International PLC
LSE:0Y5F

Watchlist Manager
Endo International PLC
LSE:0Y5F
Watchlist
Price: 861.05 USD 0.54%
Market Cap: 193.2B USD

Relative Value

There is not enough data to reliably calculate the relative value of 0Y5F.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

0Y5F Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
63.9
Median 5Y
56.6
Industry
2.6
Forward
90.8
vs History
vs Industry
Median 3Y
-51.2
Median 5Y
-51.2
Industry
21.8
Forward
978.5
vs History
vs Industry
Median 3Y
550.2
Median 5Y
481.8
Industry
16.7
vs History
vs Industry
Median 3Y
-464.7
Median 5Y
-445.8
Industry
22.7
vs History
vs Industry
Median 3Y
-36.3
Median 5Y
-44.5
Industry
2.3
vs History
vs Industry
Median 3Y
66.8
Median 5Y
58.4
Industry
2.9
Forward
93.8
vs History
vs Industry
Median 3Y
98.7
Median 5Y
96
Industry
5.5
vs History
vs Industry
Median 3Y
237.6
Median 5Y
208
Industry
13
vs History
vs Industry
Median 3Y
595.9
Median 5Y
521.5
Industry
16.6
vs History
vs Industry
Median 3Y
575
Median 5Y
503.2
Industry
15.8
vs History
vs Industry
Median 3Y
913.3
Median 5Y
799.3
Industry
19.1
vs History
vs Industry
Median 3Y
35.6
Median 5Y
31
Industry
1.9

Multiples Across Competitors

0Y5F Competitors Multiples
Endo International PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Eli Lilly and Co
NYSE:LLY
959.5B USD 16.1 52.1 35 37.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
487.2B USD 5.3 19.4 15.9 20.6
CH
Roche Holding AG
SIX:ROG
249.8B CHF 4.1 26.5 11.9 13.5
UK
AstraZeneca PLC
LSE:AZN
211.6B GBP 4.9 30 108.1 158.2
CH
Novartis AG
SIX:NOVN
206.7B CHF 4.6 17.8 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
250.9B USD 3.9 13.2 9.4 11.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.4 9.4 10.9
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
104.1B EUR 1.6 7.6 6.9 6.9
P/E Multiple
Earnings Growth PEG
IE
E
Endo International PLC
LSE:0Y5F
Average P/E: 21.6
Negative Multiple: -69.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.1
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.4
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
18%
1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
7%
1.9
US
Pfizer Inc
NYSE:PFE
14.9
31%
0.5
FR
Sanofi SA
PAR:SAN
7.6
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
E
Endo International PLC
LSE:0Y5F
Average EV/EBITDA: 398.5
321.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.9
8%
2
CH
Roche Holding AG
SIX:ROG
11.9
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.1
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
7%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
9.4
6%
1.6
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
FR
Sanofi SA
PAR:SAN
6.9
9%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
E
Endo International PLC
LSE:0Y5F
Average EV/EBIT: 1 708.3
805.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.6
14%
1.5
CH
Roche Holding AG
SIX:ROG
13.5
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
158.2
22%
7.2
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.1
9%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
6%
1.8
US
Pfizer Inc
NYSE:PFE
10.3
10%
1
FR
Sanofi SA
PAR:SAN
6.9
15%
0.5